Hsbc Holdings PLC Immuno Gen, Inc. Transaction History

Hsbc Holdings PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$12.46 - $29.95 $6.48 Million - $15.6 Million	519,779 New	519,779 $15.4 Million
Q3 2021 Nov 12, 2021	SELL	$5.02 - $6.59 $57,719 - $75,771	-11,498 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$5.79 - $8.6 $66,573 - $98,882	11,498 New	11,498 $75,000
Q1 2021 May 14, 2021	SELL	$6.5 - $10.53 $106,762 - $172,955	-16,425 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$3.7 - $7.66 $60,772 - $125,815	16,425 New	16,425 $105,000
Q3 2020 Nov 12, 2020	SELL	$3.45 - $4.89 $36,942 - $52,362	-10,708 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$3.32 - $5.34 $2,011 - $3,236	-606 Reduced 5.36%	10,708 $49,000
Q1 2020 May 15, 2020	SELL	$2.12 - $6.8 $9,938 - $31,878	-4,688 Reduced 29.3%	11,314 $39,000
Q4 2019 Feb 14, 2020	BUY	$2.25 - $5.8 $1,109 - $2,859	493 Added 3.18%	16,002 $82,000
Q3 2019 Nov 14, 2019	BUY	$2.22 - $3.39 $34,429 - $52,575	15,509 New	15,509 $38,000
Q2 2019 Aug 13, 2019	SELL	$1.8 - $3.3 $18,720 - $34,320	-10,400 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $25,064 - $61,464	10,400 New	10,400 $28,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.